Ingredion Incorporated Reports Strong First Quarter Results and Improves Full-Year Outlook 6-05-2025, 17:05

VCI Global Acquires Cutting-Edge NVIDIA H200 AI Chips Via Supermicro to Supercharge AI Cloud Business 27-01-2025, 20:33

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26